Literature DB >> 30353445

Optimization of Antipsychotic and Benzodiazepine Drugs in Patients with Severe Mental Disorders in an Intensive Case Management Program.

María-José Alvarez1, Pere Roura-Poch2, Nùria Riera2, Ana Martín2, Clara Blanch2, Judit Pons2, Josep-Manel Santos2, Santiago Escoté2.   

Abstract

The Intensive Case Management (ICM) model is a community-based program for people with severe mental illness that may reduce hospitalization and increase retention in care. The aims of this study were to analyze changes in the antipsychotic and benzodiazepine dosage in 106 patients who participated in an Individualized Service Program based on the ICM model for at least 6 months and to assess the change in the number of patients taking a high or very high dose of an antipsychotic drug and the number receiving antipsychotic polytherapy. Both the average daily dose of antipsychotic and benzodiazepine drugs and the number of patients with high doses of antipsychotic and more than one antipsychotic drug decreased significantly. Implementing the ICM program in patients with severe mental illness could help to decrease adverse drug effects and health care expenditures.

Entities:  

Keywords:  Antipsychotics; Assertive Community Treatment; Benzodiazepines; Intensive Case Management; Psychosis; Severe mental illness

Mesh:

Substances:

Year:  2018        PMID: 30353445     DOI: 10.1007/s10597-018-0349-2

Source DB:  PubMed          Journal:  Community Ment Health J        ISSN: 0010-3853


  22 in total

Review 1.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

2.  Assertive community treatment in the Netherlands: a randomized controlled trial.

Authors:  S Sytema; L Wunderink; W Bloemers; L Roorda; D Wiersma
Journal:  Acta Psychiatr Scand       Date:  2007-08       Impact factor: 6.392

3.  Community care of the acutely mentally ill.

Authors:  J Hoult
Journal:  Br J Psychiatry       Date:  1986-08       Impact factor: 9.319

4.  Antipsychotic treatment and mortality in schizophrenia.

Authors:  Minna Torniainen; Ellenor Mittendorfer-Rutz; Antti Tanskanen; Charlotte Björkenstam; Jaana Suvisaari; Kristina Alexanderson; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2014-11-24       Impact factor: 9.306

Review 5.  Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.

Authors:  Markus Dold; Chunbo Li; Donna Gillies; Stefan Leucht
Journal:  Eur Neuropsychopharmacol       Date:  2013-04-17       Impact factor: 4.600

6.  The REACT study: randomised evaluation of assertive community treatment in north London.

Authors:  Helen Killaspy; Paul Bebbington; Robert Blizard; Sonia Johnson; Fiona Nolan; Stephen Pilling; Michael King
Journal:  BMJ       Date:  2006-03-16

7.  Alternative to mental hospital treatment. I. Conceptual model, treatment program, and clinical evaluation.

Authors:  L I Stein; M A Test
Journal:  Arch Gen Psychiatry       Date:  1980-04

Review 8.  Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression.

Authors:  Tom Burns; Jocelyn Catty; Michael Dash; Chris Roberts; Austin Lockwood; Max Marshall
Journal:  BMJ       Date:  2007-07-13

9.  Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method.

Authors:  Yoshio Yamanouchi; Tsuruhei Sukegawa; Ataru Inagaki; Toshiya Inada; Takashi Yoshio; Reiji Yoshimura; Nakao Iwata
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-11       Impact factor: 5.176

10.  Atypical antipsychotic drugs and the risk of sudden cardiac death.

Authors:  Wayne A Ray; Cecilia P Chung; Katherine T Murray; Kathi Hall; C Michael Stein
Journal:  N Engl J Med       Date:  2009-01-15       Impact factor: 176.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.